Skip to main content

Professor Daniel Palmer


Molecular & Clinical Cancer Medicine
Part of
Institute of Systems, Molecular & Integrative Biology
Faculty of Health and Life Sciences

Contact

Daniel.Palmer@liverpool.ac.uk

+44 (0)151 706 4172

+44 (0)151 706 4177

Publications

What type of publication do you want to show?

2023

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe

Taieb, J., Seufferlein, T., Reni, M., Palmer, D. H., Bridgewater, J. A., Cubillo, A., . . . Macarulla, T. (2023). Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe. BMC CANCER, 23(1). doi:10.1186/s12885-023-11377-1

DOI
10.1186/s12885-023-11377-1
Journal article

PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research

Jones, R. P., Mielgo, A., Schmid, M., Bury, D., Andrews, T., Burdak-Rothkamm, S., . . . Vimalachandran, D. (2023). PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research. BRITISH JOURNAL OF SURGERY. doi:10.1093/bjs/znad097

DOI
10.1093/bjs/znad097
Journal article

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma

de Andres, M. P., Jackson, R. J., Felipe, I., Zagorac, S., Pilarsky, C., Schlitter, A. M., . . . Real, F. X. (2023). GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. GUT, 72(3), 535-548. doi:10.1136/gutjnl-2021-325803

DOI
10.1136/gutjnl-2021-325803
Journal article

2022

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.

Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., . . . European Study Group for Pancreatic Cancer. (2022). Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.. The lancet. Gastroenterology & hepatology, S2468-1253(22)00348-X. doi:10.1016/s2468-1253(22)00348-x

DOI
10.1016/s2468-1253(22)00348-x
Journal article

United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer

Oldfield, L., Stott, M., Hanson, R., Jackson, R. J., Reynolds, W., Chandran-Gorner, V., . . . Costello, E. (2022). United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer. BMJ OPEN, 12(10). doi:10.1136/bmjopen-2022-068010

DOI
10.1136/bmjopen-2022-068010
Journal article

Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study

Bridgewater, J., Fletcher, P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., . . . Primrose, J. (2022). Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. JOURNAL OF CLINICAL ONCOLOGY, 40(18), 2048-+. doi:10.1200/JCO.21.02568

DOI
10.1200/JCO.21.02568
Journal article

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Verset, G., Borbath, I., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., . . . Zhu, A. X. (2022). Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. CLINICAL CANCER RESEARCH, 28(12), 2547-2554. doi:10.1158/1078-0432.CCR-21-3807

DOI
10.1158/1078-0432.CCR-21-3807
Journal article

Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-PIE) trial: study protocol for a feasibility randomised controlled trial

Rai, Z. L., Ranieri, V., Palmer, D. H., Littler, P., Ghaneh, P., Gurusamy, K., . . . Davidson, B. R. (2022). Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-PIE) trial: study protocol for a feasibility randomised controlled trial. BMJ OPEN, 12(5). doi:10.1136/bmjopen-2021-050166

DOI
10.1136/bmjopen-2021-050166
Journal article

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

Kudo, M., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D. H., . . . Zhu, A. X. (2022). Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. EUROPEAN JOURNAL OF CANCER, 167, 1-12. doi:10.1016/j.ejca.2022.02.009

DOI
10.1016/j.ejca.2022.02.009
Journal article

Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma (vol 41, pg 795, 2021)

Ryoo, B. -Y., Palmer, D. H., Park, S. R., Rimassa, L., Sarker, D., Daniele, B., . . . Lim, H. Y. (2022). Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma (vol 41, pg 795, 2021). CLINICAL DRUG INVESTIGATION, 42(3), 283. doi:10.1007/s40261-022-01132-y

DOI
10.1007/s40261-022-01132-y
Journal article

A randomised phase II clinical trial of low-dose cyclophosphamide and transarterial chemoembolization (TACE) with or without vaccination with dendritic cells (DC) pulsed with HepG2 lysate ex vivo in patients with hepatocellular carcinoma (HCC): The ImmunoTACE trial.

Ting Ma, Y., Kirkham, A., Curbishley, S., Rowe, A., Blahova, M., Mehrzad, H., . . . Adams, D. H. (2022). A randomised phase II clinical trial of low-dose cyclophosphamide and transarterial chemoembolization (TACE) with or without vaccination with dendritic cells (DC) pulsed with HepG2 lysate ex vivo in patients with hepatocellular carcinoma (HCC): The ImmunoTACE trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/

Conference Paper

Entity-independent Safety and Efficacy of Erdafitinib in Patients with advanced solid Tumors with pre-specified genomic Aberrations of <i>FGFR</i> (RAGNAR Interim Analysis)

Schuler, M., Loriot, Y., Iyer, G., Witt, O., Doi, T., Qin, S., . . . Pant, S. (2022). Entity-independent Safety and Efficacy of Erdafitinib in Patients with advanced solid Tumors with pre-specified genomic Aberrations of <i>FGFR</i> (RAGNAR Interim Analysis). In ONCOLOGY RESEARCH AND TREATMENT Vol. 45 (pp. 27-28). Retrieved from https://www.webofscience.com/

Conference Paper

Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.

Borbath, I., Van Laethem, J. -L., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., . . . Vogel, A. (2022). Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/

Conference Paper

TARGET National: A UK-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials

Ortega-Franco, A., Darlington, E., Carter, L., Cook, N., Graham, D. M., Thistlethwaite, F., . . . Krebs, M. (2022). TARGET National: A UK-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/

Conference Paper

2021

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer

Hashimoto, A., Sarker, D., Reebye, V., Jarvis, S., Sodergren, M. H., Kossenkov, A., . . . Gabrilovich, D. I. (2021). Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. CLINICAL CANCER RESEARCH, 27(21), 5961-5978. doi:10.1158/1078-0432.CCR-21-0986

DOI
10.1158/1078-0432.CCR-21-0986
Journal article

Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC)

Vogel, A., Frenette, C., Sung, M. W., Daniele, B., Baron, A. D., Chan, S. L., . . . Kudo, M. (2020). Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/

Conference Paper

Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma

Ryoo, B. -Y., Palmer, D. H., Park, S. R., Rimassa, L., Sarker, D., Daniele, B., . . . Lim, H. Y. (2021). Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. CLINICAL DRUG INVESTIGATION, 41(9), 795-808. doi:10.1007/s40261-021-01063-0

DOI
10.1007/s40261-021-01063-0
Journal article

Human Mass Balance and Metabolite Profiling of [<SUP>14</SUP>C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer

Mu, S., Palmer, D., Fitzgerald, R., Andreu-Vieyra, C., Zhang, H., Tang, Z., . . . Sahasranaman, S. (2021). Human Mass Balance and Metabolite Profiling of [<SUP>14</SUP>C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 10(9), 1108-1120. doi:10.1002/cpdd.943

DOI
10.1002/cpdd.943
Journal article

Second-line FOLFOX chemotherapy for advanced biliary tract cancer

Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., . . . Valle, J. W. (2021). Second-line FOLFOX chemotherapy for advanced biliary tract cancer. LANCET ONCOLOGY, 22(7), E288-E289. Retrieved from https://www.webofscience.com/

Journal article

The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients: a randomised controlled trial (The EMPOWER Trial)

Loughney, L., West, M. A., Moyses, H., Bates, A., Kemp, G. J., Hawkins, L., . . . Jack, S. (2021). The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients: a randomised controlled trial (The EMPOWER Trial). PERIOPERATIVE MEDICINE, 10(1). doi:10.1186/s13741-021-00190-8

DOI
10.1186/s13741-021-00190-8
Journal article

Organoid Models of Cholangiocarcinoma

Gilbert, T., Quinn, M., Goldring, C., Palmer, D., Braconi, C., & Malik, H. (2021). Organoid Models of Cholangiocarcinoma. In Diagnosis and Management of Cholangiocarcinoma (pp. 495-508). Springer International Publishing. doi:10.1007/978-3-030-70936-5_23

DOI
10.1007/978-3-030-70936-5_23
Chapter

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.

Van Laethem, J. -L., Borbath, I., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., . . . Zhu, A. X. (2021). Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.15_suppl.4074

DOI
10.1200/JCO.2021.39.15_suppl.4074
Conference Paper

Phase III study of NUC-1031+cisplatin versus gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Knox, J. J., McNamara, M. G., Goyal, L., Cosgrove, D., Springfeld, C., Sjoquist, K. M., . . . Valle, J. W. (2021). Phase III study of NUC-1031+cisplatin versus gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.15_suppl.TPS4164

DOI
10.1200/JCO.2021.39.15_suppl.TPS4164
Conference Paper

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., . . . Valle, J. W. (2021). Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. LANCET ONCOLOGY, 22(5), 690-701. doi:10.1016/S1470-2045(21)00027-9

DOI
10.1016/S1470-2045(21)00027-9
Journal article

A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)

McNamara, M. G., Bridgewater, J., Palmer, D. H., Faluyi, O., Wasan, H., Patel, A., . . . Valle, J. W. (2021). A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ONCOLOGIST, 26(4), E669-E678. doi:10.1002/onco.13598

DOI
10.1002/onco.13598
Journal article

Erratum to "Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome"

Lee, R. J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., . . . Armstrong, A. C. (2021). Erratum to "Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome". ESMO OPEN, 6(2). doi:10.1016/j.esmoop.2021.100056

DOI
10.1016/j.esmoop.2021.100056
Journal article

Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic"

Jones, C. M., Radhakrishna, G., Aitken, K., Bridgewater, J., Corrie, P., Eatock, M., . . . Mukherjee, S. (2021). Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". BRITISH JOURNAL OF CANCER, 124(3), 679-680. doi:10.1038/s41416-020-01133-8

DOI
10.1038/s41416-020-01133-8
Journal article

Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome

Lee, R. J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., . . . Armstrong, A. C. (2021). Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome. ESMO OPEN, 6(1). doi:10.1016/j.esmoop.2020.100005

DOI
10.1016/j.esmoop.2020.100005
Journal article

Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.

Bhogal, T., Khan, U. T., Lee, R., Stockdale, A., Hesford, C., Potti-Dhananjaya, V., . . . Palmieri, C. (2021). Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.. Leukemia & lymphoma, 1-16. doi:10.1080/10428194.2021.1876865

DOI
10.1080/10428194.2021.1876865
Journal article

A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).

Sangro, B., Harding, J. J., Johnson, M., Palmer, D. H., Edeline, J., Abou-Alfa, G. K., . . . Kudo, M. (2021). A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.3_suppl.TPS349

DOI
10.1200/JCO.2021.39.3_suppl.TPS349
Conference Paper

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.

Van Laethem, J. -L., Borbath, I., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., . . . Zhu, A. X. (2021). Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.3_suppl.297

DOI
10.1200/JCO.2021.39.3_suppl.297
Conference Paper

Phase III study of NUC-1031+cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Knox, J. J., McNamara, M. G., Goyal, L., Cosgrove, D., Springfeld, C., Sjoquist, K. M., . . . Valle, J. W. (2021). Phase III study of NUC-1031+cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.3_suppl.TPS351

DOI
10.1200/JCO.2021.39.3_suppl.TPS351
Conference Paper

Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.

Taieb, J., Hammel, P., Reni, M., Palmer, D. H., Bridgewater, J. A., Cubillo, A., . . . Macarulla, T. (2021). Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.3_suppl.391

DOI
10.1200/JCO.2021.39.3_suppl.391
Conference Paper

2020

PANasta Trial: Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy-A double-blinded multi-centered trial, trial results.

Halloran, C., Neoptolemos, J. P., Platt, K., Jackson, R., Reddy, S., Oreily, D., . . . Ghaneh, P. (2020). PANasta Trial: Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy-A double-blinded multi-centered trial, trial results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/

Conference Paper

MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-a, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Sarker, D., Plummer, R., Meyer, T., Sodergren, M. H., Basu, B., Chee, C. E., . . . Habib, N. (2020). MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-a, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. CLINICAL CANCER RESEARCH, 26(15), 3936-3946. doi:10.1158/1078-0432.CCR-20-0414

DOI
10.1158/1078-0432.CCR-20-0414
Journal article

NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.

Kapacee, Z. A., Knox, J. J., Palmer, D., Blagden, S. P., Lamarca, A., Valle, J. W., & McNamara, M. G. (2020). NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.. Medical oncology (Northwood, London, England), 37(7), 61. doi:10.1007/s12032-020-01386-6

DOI
10.1007/s12032-020-01386-6
Journal article

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

Palmer, D. H., Valle, J. W., Ting Ma, Y., Faluyi, O., Neoptolemos, J. P., Jensen Gjertsen, T., . . . Dueland, S. (2020). TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. BRITISH JOURNAL OF CANCER, 122(7), 971-977. doi:10.1038/s41416-020-0752-7

DOI
10.1038/s41416-020-0752-7
Journal article

Role of locoregional therapies in the wake of systemic therapy

Palmer, D. H., Malagari, K., & Kulik, L. M. (2020). Role of locoregional therapies in the wake of systemic therapy. JOURNAL OF HEPATOLOGY, 72(2), 277-287. doi:10.1016/j.jhep.2019.09.023

DOI
10.1016/j.jhep.2019.09.023
Journal article

Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study

Palmer, D. H., Hawkins, N. S., Vilgrain, V., Pereira, H., Chatellier, G., & Ross, P. J. (2020). Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. FUTURE ONCOLOGY, 16(1), 4315-4325. doi:10.2217/fon-2019-0658

DOI
10.2217/fon-2019-0658
Journal article

ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.

Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Valle, J. W., Cunningham, D., Wadsley, J., . . . Buchler, M. W. (2020). ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/

Conference Paper

First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Sarker, D., Sodergren, M., Plummer, E. R., Basu, B., Meyer, T., Huang, K. -W., . . . Habib, N. A. (2020). First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/

Conference Paper

NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)

Knox, J. J., McNamara, M. G., Goyal, L., Doherty, M., Springfeld, C., Park, J. O., . . . Valle, J. W. (2020). NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/

Conference Paper

Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Sarker, D., Sodergren, M., Plummer, E. R., Basu, B., Meyer, T., Huang, K. -W., . . . Habib, N. A. (2020). Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/

Conference Paper

Real-world experience of regorafenib in patients with hepatocellular carcinoma: A multicenter United Kingdom study

Ross, P. J., Ma, Y. T., Palmer, D. H., Lythgoe, M. P., Merrick, S., Samson, A., . . . Thillai, K. (2020). Real-world experience of regorafenib in patients with hepatocellular carcinoma: A multicenter United Kingdom study. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/

Conference Paper

Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC)

Kudo, M., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D. H., . . . Zhu, A. X. (2020). Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38. Retrieved from https://www.webofscience.com/

Conference Paper

2019

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J. -W., . . . Kang, Y. -K. (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. CANCER DISCOVERY, 9(12), 1696-1707. doi:10.1158/2159-8290.CD-19-0555

DOI
10.1158/2159-8290.CD-19-0555
Journal article

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Jones, R. P., Psarelli, E. -E., Jackson, R., Ghaneh, P., Halloran, C. M., Palmer, D. H., . . . Millat, B. (2019). Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA SURGERY, 154(11), 1038-1048. doi:10.1001/jamasurg.2019.3337

DOI
10.1001/jamasurg.2019.3337
Journal article

Evaluation of the utility of prognostic models for patients with resected hilar cholangiocarcinoma

Bird, N. T. E., Manu, N., Quinn, L., Needham, A., Jones, R., Fenwick, S., . . . Malik, H. (2019). Evaluation of the utility of prognostic models for patients with resected hilar cholangiocarcinoma. HPB, 21(10), 1376-1384. doi:10.1016/j.hpb.2019.02.014

DOI
10.1016/j.hpb.2019.02.014
Journal article

Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged

Alabraba, E., Joshi, H., Bird, N., Griffin, R., Sturgess, R., Stern, N., . . . Malik, H. (2019). Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. EJSO, 45(9), 1660-1667. doi:10.1016/j.ejso.2019.04.002

DOI
10.1016/j.ejso.2019.04.002
Journal article

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC plus mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., . . . Valle, J. W. (2019). ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC plus mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. doi:10.1200/JCO.2019.37.15_suppl.4003

DOI
10.1200/JCO.2019.37.15_suppl.4003
Conference Paper

NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.

Knox, J. J., McNamara, M. G., Palmer, D. H., Evans, T. R. J., Goldstein, D., Bridgewater, J. A., & Valle, J. W. (2019). NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. doi:10.1200/JCO.2019.37.15_suppl.TPS4156

DOI
10.1200/JCO.2019.37.15_suppl.TPS4156
Conference Paper

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., . . . Grp, B. I. L. C. A. P. S. (2019). Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. LANCET ONCOLOGY, 20(5), 663-673. doi:10.1016/S1470-2045(18)30915-X

DOI
10.1016/S1470-2045(18)30915-X
Journal article

Chemotherapy for pancreatic cancer

Springfeld, C., Jaeger, D., Buechler, M. W., Strobel, O., Hackert, T., Palmer, D. H., & Neoptolemos, J. P. (2019). Chemotherapy for pancreatic cancer. PRESSE MEDICALE, 48(3), E159-E174. doi:10.1016/j.lpm.2019.02.025

DOI
10.1016/j.lpm.2019.02.025
Journal article

The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma

Ghaneh, P., Kleeff, J., Halloran, C. M., Raraty, M., Jackson, R., Melling, J., . . . Smith, C. (2019). The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 269(03), 520-529. doi:10.1097/SLA.0000000000002557

DOI
10.1097/SLA.0000000000002557
Journal article

ABC-06 | A randomised phase III study of Active Symptom Control (ASC) with/without mFOLFOX after progression to Cisplatin-Gemcitabine chemotherapy for patients with advanced biliary tract cancers

Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., . . . Valle, J. W. (2019). ABC-06 | A randomised phase III study of Active Symptom Control (ASC) with/without mFOLFOX after progression to Cisplatin-Gemcitabine chemotherapy for patients with advanced biliary tract cancers. In BRITISH JOURNAL OF CANCER Vol. 121 (pp. 19). Retrieved from https://www.webofscience.com/

Conference Paper

First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-α, in patients with advanced hepatocellular cancer (HCC)

Sarker, D., Plummer, R., Basu, B., Meyer, T., Ma, Y. -T., Evans, J., . . . Habib, N. (2019). First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-α, in patients with advanced hepatocellular cancer (HCC). In ANNALS OF ONCOLOGY Vol. 30 (pp. 168-+). Retrieved from https://www.webofscience.com/

Conference Paper

Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.

Javed, M. A., Beyer, G., Le, N., Vinci, A., Wong, H., Palmer, D., . . . Krug, S. (2019). Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 19(1), 97-104. doi:10.1016/j.pan.2018.10.003

DOI
10.1016/j.pan.2018.10.003
Journal article

Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted osimetry in the SARAH trial

Hawkins, N. S., Ross, P. J., Palmer, D. H., Chatellier, G., Pereira, H., & Vilgrain, V. (2019). Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted osimetry in the SARAH trial. In ANNALS OF ONCOLOGY Vol. 30. Retrieved from https://www.webofscience.com/

Conference Paper

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma (PDAC) in the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Neoptolemos, J. P., Jones, R. P., Psarelli, E. E., Jackson, R., Ghaneh, P., Halloran, C. M., . . . Buechler, M. W. (2019). Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma (PDAC) in the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. In PANCREAS Vol. 48 (pp. 1497-1498). Retrieved from https://www.webofscience.com/

Conference Paper

Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: A post-hoc analysis of the SARAH trial

Palmer, D. H., Hawkins, N. S., Vilgrain, V., Pereira, H., Chatellier, G., & Ross, P. J. (2019). Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: A post-hoc analysis of the SARAH trial. In ANNALS OF ONCOLOGY Vol. 30 (pp. 282). Retrieved from https://www.webofscience.com/

Conference Paper

hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer

Hale, J., Evans, A., Aughton, K., Elander, N. O., Ghaneh, P., Neoptolemos, J. P., . . . Greenhalf, W. (2019). hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer. In PANCREAS Vol. 48 (pp. 1436-1437). Retrieved from https://www.webofscience.com/

Conference Paper

2018

Immune Cell and Stromal Signature Associated with Progression-free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma

Mahajan, U. M., Langhoff, E., Goni, E., Costello, E., Greenhalf, W., Halloran, C. M., . . . Mayerle, J. (2018). Immune Cell and Stromal Signature Associated with Progression-free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology, 155(05), 1625-1639.E2. doi:10.1053/j.gastro.2018.08.009

DOI
10.1053/j.gastro.2018.08.009
Journal article

ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma

Palmer, D. H., Ross, P. J., Silcocks, P., Greenhalf, W., Faluyi, O., Ma, Y. T., . . . Bridgewater, J. (2018). ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma. In ANNALS OF ONCOLOGY Vol. 29. Retrieved from https://www.webofscience.com/

Conference Paper

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Stainthorpe, A., Greenhalgh, J., Bagust, A., Richardson, M., Boland, A., Beale, S., . . . Palmer, D. (2018). Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1153-1163. doi:10.1007/s40273-018-0646-1

DOI
10.1007/s40273-018-0646-1
Journal article

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., . . . Kudo, M. (2018). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. LANCET ONCOLOGY, 19(7), 940-952. doi:10.1016/S1470-2045(18)30351-6

DOI
10.1016/S1470-2045(18)30351-6
Journal article

Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.

Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D. H., . . . Kudo, M. (2018). Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.4020

DOI
10.1200/JCO.2018.36.15_suppl.4020
Conference Paper

Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.

Sarker, D., Plummer, E. R., Basu, B., Meyer, T., Huang, K. -W., Evans, T. R. J., . . . Habib, N. A. (2018). Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.2509

DOI
10.1200/JCO.2018.36.15_suppl.2509
Conference Paper

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

Palmer, D. H., Ma, Y. T., Peck-Radosavljevic, M., Ross, P., Graham, J., Fartoux, L., . . . Meyer, T. (2018). A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. British Journal of Cancer, 118, 1162-1168. doi:10.1038/s41416-018-0051-8

DOI
10.1038/s41416-018-0051-8
Journal article

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy

Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., . . . Canc, E. S. G. P. (2018). Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 118, 1084-1088. doi:10.1038/s41416-018-0005-1

DOI
10.1038/s41416-018-0005-1
Journal article

Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Fleeman, N., Abdulla, A., Bagust, A., Beale, S., Richardson, M., Stainthorpe, A., . . . Palmer, D. (2018). Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36(3), 289-299. doi:10.1007/s40273-017-0592-3

DOI
10.1007/s40273-017-0592-3
Journal article

ABC-08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers.

McNamara, M. G., Bridgewater, J. A., Palmer, D. H., Wasan, H. S., Ryder, D., Gnanaranjan, C., . . . Valle, J. W. (2018). ABC-08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.4_suppl.TPS544

DOI
10.1200/JCO.2018.36.4_suppl.TPS544
Conference Paper

ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma.

Palmer, D. H., Ross, P. J., Silcocks, P., Greenhalf, W., Faluyi, O. O., Ma, Y. T., . . . Neoptolemos, J. P. (2018). ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.4_suppl.TPS537

DOI
10.1200/JCO.2018.36.4_suppl.TPS537
Conference Paper

Cytoplasmic HuR Status Predicts Disease-Free Survival in Resected Pancreatic Cancer: A Post-Hoc Analysis from the International Multi-Institutional Phase III ESPAC-3 Clinical Trial

Halloran, C. M. (2018). Cytoplasmic HuR Status Predicts Disease-Free Survival in Resected Pancreatic Cancer: A Post-Hoc Analysis from the International Multi-Institutional Phase III ESPAC-3 Clinical Trial. Annals of Surgery, 267(2), 364-369. doi:10.1097/SLA.0000000000002088

DOI
10.1097/SLA.0000000000002088
Journal article

KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

Zhu, A. X., Finn, R. S., Cattan, S., Edeline, J., Ogasawara, S., Palmer, D. H., . . . Kudo, M. (2018). KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.4_suppl.209

DOI
10.1200/JCO.2018.36.4_suppl.209
Conference Paper

Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management

Sutton, P. A., Jithesh, P. V., Jones, R. P., Evans, J. P., Vimalachandran, D., Malik, H. Z., . . . Kitteringham, N. R. (2018). Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management. EJSO - European Journal of Surgical Oncology, 44(1), 115-121. doi:10.1016/j.ejso.2017.10.211

DOI
10.1016/j.ejso.2017.10.211
Journal article

PhotoChemical internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma: Results from a phase I dose escalation trial

Trojan, J., Sturgess, R., Palmer, D. H., Neu, B., Kasper, S., Dechene, A., . . . Olivecrona, H. (2018). PhotoChemical internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma: Results from a phase I dose escalation trial. In ANNALS OF ONCOLOGY Vol. 29. Retrieved from https://www.webofscience.com/

Conference Paper

2017

Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score

Edeline, J., Blanc, J. -F., Campillo-Gimenez, B., Ma, Y. -T., King, J., Faluyi, O., . . . Meyer, T. (2017). Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. European Journal of Cancer, 86, 135-142. doi:10.1016/j.ejca.2017.08.036

DOI
10.1016/j.ejca.2017.08.036
Journal article

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R., . . . Palmer, D. H. (2017). Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2(8), 565-575. doi:10.1016/S2468-1253(17)30156-5

DOI
10.1016/S2468-1253(17)30156-5
Journal article

Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine: A Pan-European study.

Javed, M. A., Beyer, G., Le, N. N. H., Vinci, A., Wong, H., Palmer, D. H., . . . Krug, S. (2017). Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine: A Pan-European study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35. doi:10.1200/JCO.2017.35.15_suppl.e15774

DOI
10.1200/JCO.2017.35.15_suppl.e15774
Conference Paper

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial

Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., . . . Neoptolemos, J. P. (2017). Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology, 18(4), 486-499. doi:10.1016/S1470-2045(17)30084-0

DOI
10.1016/S1470-2045(17)30084-0
Journal article

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., . . . Büchler, M. W. (2017). Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.. Lancet (London, England), 389(10073), 1011-1024. doi:10.1016/s0140-6736(16)32409-6

DOI
10.1016/s0140-6736(16)32409-6
Journal article

Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy

Bird, N. T. E., Elmasry, M., Jones, R., Psarelli, E., Dodd, J., Malik, H., . . . Palmer, D. (2017). Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. BRITISH JOURNAL OF SURGERY, 104(4), 328-336. doi:10.1002/bjs.10482

DOI
10.1002/bjs.10482
Journal article

Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinoma

Bird, N., Elmasry, M., Jones, R., Elniel, M., Kelly, M., Palmer, D., . . . Malik, H. (2017). Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinoma. BRITISH JOURNAL OF SURGERY, 104(4), 418-425. doi:10.1002/bjs.10399

DOI
10.1002/bjs.10399
Journal article

A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).

Corrie, P., Qian, W., Basu, B., Jodrell, D. I., Falk, S., Iwuji, C., . . . Valle, J. W. (2017). A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35. doi:10.1200/JCO.2017.35.4_suppl.342

DOI
10.1200/JCO.2017.35.4_suppl.342
Conference Paper

2016

A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma

Edeline, J., Blanc, J. -F., Johnson, P., Campillo-Gimenez, B., Ross, P., Ma, Y. T., . . . Meyer, T. (2016). A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver international : official journal of the International Association for the Study of the Liver, 36(12), 1821-1828. doi:10.1111/liv.13170

DOI
10.1111/liv.13170
Journal article

Intensified chemotherapy for metastatic pancreatic cancer: interim analysis of a large retrospective pan-European database and real life evaluation

Krug, S., Beyer, G., Javed, M. A., Le, N., Vinci, A., Morgan, R. D., . . . Schober, M. (2016). Intensified chemotherapy for metastatic pancreatic cancer: interim analysis of a large retrospective pan-European database and real life evaluation. In ANNALS OF ONCOLOGY Vol. 27. doi:10.1093/annonc/mdw371.68

DOI
10.1093/annonc/mdw371.68
Conference Paper

TACE 2: A randomized placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC) Background

Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M., Strugess, R., . . . Palmer, D. H. (2016). TACE 2: A randomized placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC) Background. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.4018

DOI
10.1200/JCO.2016.34.15_suppl.4018
Conference Paper

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib

Meyer, T., Palmer, D. H., Cheng, A. -L., Hocke, J., Loembe, A. -B., & Yen, C. -J. (2016). mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.4086

DOI
10.1200/JCO.2016.34.15_suppl.4086
Conference Paper

Quality of life, long-term survivors and long-term outcome from the ABC-02 study

Bridgewater, J., Lopes, A., Palmer, D., Cunningham, D., Anthoney, A., Maraveyas, A., . . . Wasan, H. (2016). Quality of life, long-term survivors and long-term outcome from the ABC-02 study. BRITISH JOURNAL OF CANCER, 114(9), 965-971. doi:10.1038/bjc.2016.64

DOI
10.1038/bjc.2016.64
Journal article

NORE1A induction by membrane-bound CD40L (mCD40L) contributes to CD40L-induced cell death and G1 growth arrest in p21-mediated mechanism

Elmetwali, T., Salman, A., & Palmer, D. H. (2016). NORE1A induction by membrane-bound CD40L (mCD40L) contributes to CD40L-induced cell death and G1 growth arrest in p21-mediated mechanism. CELL DEATH & DISEASE, 7. doi:10.1038/cddis.2016.52

DOI
10.1038/cddis.2016.52
Journal article

Randomized clinical trial of prehabilitation before planned liver resection

Dunne, D. F. J., Jack, S., Jones, R. P., Jones, L., Lythgoe, D. T., Malik, H. Z., . . . Fenwick, S. W. (2016). Randomized clinical trial of prehabilitation before planned liver resection. BRITISH JOURNAL OF SURGERY, 103(5), 504-512. doi:10.1002/bjs.10096

DOI
10.1002/bjs.10096
Journal article

A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.

Macarulla, T., Tabernero, J., Palmer, D. H., Sharma, S., Yu, K. H., Sellami, D. B., . . . Kwak, E. L. (2016). A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/jco.2016.34.4_suppl.371

DOI
10.1200/jco.2016.34.4_suppl.371
Conference Paper

From mice to men: Murine models of colorectal cancer for use in translational research

Evans, J. P., Sutton, P. A., Winiarski, B. K., Fenwick, S. W., Malik, H. Z., Vimalachandran, D., . . . Kitteringham, N. R. (2016). From mice to men: Murine models of colorectal cancer for use in translational research. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 98, 94-105. doi:10.1016/j.critrevonc.2015.10.009

DOI
10.1016/j.critrevonc.2015.10.009
Journal article

The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial

Loughney, L., West, M. A., Kemp, G. J., Rossiter, H. B., Burke, S. M., Cox, T., . . . Jack, S. (2016). The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial. TRIALS, 17. doi:10.1186/s13063-015-1149-4

DOI
10.1186/s13063-015-1149-4
Journal article

Effect of Valvular Surgery in Carcinoid Heart Disease: An Observational Cohort Study

Edwards, N. C., Yuan, M., Nolan, O., Pawade, T. A., Oelofse, T., Singh, H., . . . Steeds, R. P. (2016). Effect of Valvular Surgery in Carcinoid Heart Disease: An Observational Cohort Study. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 101(1), 182-189. doi:10.1210/jc.2015-3295

DOI
10.1210/jc.2015-3295
Journal article

Gene expression profiling study in bladder cancer;

Hussain, S. A., Palmer, D. H., Sacco, J., Lloyd, B., Puthen, J., Collins, S. I., . . . James, N. D. (2016). Gene expression profiling study in bladder cancer;. British Journal of Cancer.

Journal article

Hepatocellular carcinoma

Jones, R. P., Palmer, D. H., & Malik, H. Z. (2016). Hepatocellular carcinoma. In Surgical Oncology: Theory and Multidisciplinary Practice, Second Edition (pp. 429-440).

Chapter

2015

Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma

Palmer, D. H., & Johnson, P. J. (2015). Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. CANCER AND METASTASIS REVIEWS, 34(3), 497-509. doi:10.1007/s10555-015-9580-2

DOI
10.1007/s10555-015-9580-2
Journal article

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., . . . Bridgewater, J. A. (2015). Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. The Lancet Oncology, 16(8), 967-978. doi:10.1016/S1470-2045(15)00139-4

DOI
10.1016/S1470-2045(15)00139-4
Journal article

Prognostic molecular markers in resected extrahepatic biliary tract cancers; a systematic review and meta-analysis of immunohistochemically detected biomarkers

Jones, R. P., Bird, N. T. E., Smith, R. A., Palmer, D. H., Fenwick, S. W., Poston, G. J., & Malik, H. Z. (2015). Prognostic molecular markers in resected extrahepatic biliary tract cancers; a systematic review and meta-analysis of immunohistochemically detected biomarkers. BIOMARKERS IN MEDICINE, 9(8), 763-775. doi:10.2217/BMM.15.48

DOI
10.2217/BMM.15.48
Journal article

MODULATION OF NRF2 ALTERS THE RESPONSIVENESS OF COLORECTAL CANCER CELLS TO IRINOTECAN

Evans, J. P., Winiarski, B. K., Sutton, P. A., Palmer, D. H., & Kitteringham, N. (2015). MODULATION OF NRF2 ALTERS THE RESPONSIVENESS OF COLORECTAL CANCER CELLS TO IRINOTECAN. In GUT Vol. 64 (pp. A531). doi:10.1136/gutjnl-2015-309861.1160

DOI
10.1136/gutjnl-2015-309861.1160
Conference Paper

A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma

Palmer, D. H., Dueland, S., Valle, J. W., Otterhaug, T., Eriksen, J. A., Muller, H., . . . Miller, R. M. (2015). A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.15_suppl.4121

DOI
10.1200/jco.2015.33.15_suppl.4121
Conference Paper

Changes in plasma biomarkers over time in patients (pts) with advanced biliary tract cancer (ABC) treated in the UK ABC-03 randomized phase II trial

Backen, A. C., McNamara, M. G., Lopes, A., Wasan, H., Palmer, D. H., Duggan, M., . . . Valle, J. W. (2015). Changes in plasma biomarkers over time in patients (pts) with advanced biliary tract cancer (ABC) treated in the UK ABC-03 randomized phase II trial. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.15_suppl.4085

DOI
10.1200/jco.2015.33.15_suppl.4085
Conference Paper

Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.

Meyer, T., Palmer, D. H., Chao, Y., Choi, C., Deptala, A., Fartoux, L., . . . Cheng, A. -L. (2015). Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.15_suppl.4074

DOI
10.1200/jco.2015.33.15_suppl.4074
Conference Paper

Predicting response to treatment for colorectal cancer: a review of relevant mechanisms and potential biomarkers

Sutton, P. A., Jones, R. P., Evans, J. P., Kitteringham, N., Goldring, C., Palmer, D. H., . . . Malik, H. Z. (2015). Predicting response to treatment for colorectal cancer: a review of relevant mechanisms and potential biomarkers. COLORECTAL CANCER, 4(2), 85-95. doi:10.2217/CRC.15.11

DOI
10.2217/CRC.15.11
Journal article

Evidence of adjuvant chemotherapy of ductal pancreatic cancer

Sultana, A., Halloran, C., Palmer, D., Ghaneh, P., Cox, T., & Neoptolemos, J. P. (2015). Evidence of adjuvant chemotherapy of ductal pancreatic cancer. In PANCREATIC CANCER, CYSTIC NEOPLASMS, AND ENDOCRINE TUMORS: DIAGNOSIS AND MANAGEMENT (pp. 94-102). Retrieved from https://www.webofscience.com/

Chapter

Proteomic analysis to identify biomarkers in the primary tumour that predict response to neoadjuvant chemotherapy in liver metastases

Sutton, P., Evans, J., Jones, R., Malik, H., Vimalachandran, D., Palmer, D., . . . Kitteringham, N. (2015). Proteomic analysis to identify biomarkers in the primary tumour that predict response to neoadjuvant chemotherapy in liver metastases. LANCET, 385, 95. Retrieved from https://www.webofscience.com/

Journal article

Assessment of liver function in patients with hepatocellular caicnoma: a new evidence-based approach - The ALBI Grade

Johnson, P., & Berhane, S. (2015). Assessment of liver function in patients with hepatocellular caicnoma: a new evidence-based approach - The ALBI Grade. Journal of Clinical Oncology, 33(6), 550-558. doi:10.1200/JCO.2014.57.9151

DOI
10.1200/JCO.2014.57.9151
Journal article

Evaluation of a novel tissue stabilization gel to facilitate clinical sampling for translational research in surgical trials

Sutton, P. A., Jones, R. P., Morrison, F., Goldring, C. E., Park, B. K., Palmer, D. H., . . . Kitteringham, N. R. (2015). Evaluation of a novel tissue stabilization gel to facilitate clinical sampling for translational research in surgical trials. BRITISH JOURNAL OF SURGERY, 102(2), E124-E132. doi:10.1002/bjs.9678

DOI
10.1002/bjs.9678
Journal article

Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Palmer, D. H., Ma, Y. T., Peck-Radosavljevic, M., Ross, P. J., Graham, J. S., Fartoux, L., . . . Meyer, T. (2015). Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.3_suppl.238

DOI
10.1200/jco.2015.33.3_suppl.238
Conference Paper

2014

Hepatocellular carcinoma

Palmer, D. H., & Johnson, P. J. (2014). Hepatocellular carcinoma. In Treatment of Cancer (pp. 201-212). CRC Press. doi:10.1201/b17751-9

DOI
10.1201/b17751-9
Chapter

Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushing's syndrome: treatment response with chemotherapy

Rajeev, S. P., McDougall, S., Terlizzo, M., Palmer, D., Daousi, C., & Cuthbertson, D. J. (2014). Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushing's syndrome: treatment response with chemotherapy. BMC ENDOCRINE DISORDERS, 14. doi:10.1186/1472-6823-14-70

DOI
10.1186/1472-6823-14-70
Journal article

Chemotherapy, radiotherapy, chemoradiotherapy and combination therapy in localised and locally advanced pancreatic cancer

Sultana, A., Jackson, R. J., Cox, T., Palmer, D., Neoptolemos, J., & Ghaneh, P. (n.d.). Chemotherapy, radiotherapy, chemoradiotherapy and combination therapy in localised and locally advanced pancreatic cancer. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd011044

DOI
10.1002/14651858.cd011044
Journal article

Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study.

Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M. J., Skowronska, A., . . . Kumada, T. (2014). Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.4094

DOI
10.1200/jco.2014.32.15_suppl.4094
Conference Paper

Proteomic analysis of primary colorectal cancer to generate response biomarkers for liver metastases

Sutton, P. A., Jones, R., Rowe, C., Jenkins, R., Malik, H. Z., Vimalachandran, D., . . . Palmer, D. H. (2014). Proteomic analysis of primary colorectal cancer to generate response biomarkers for liver metastases. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.e14535

DOI
10.1200/jco.2014.32.15_suppl.e14535
Conference Paper

Proteomic profiling of the diagnostic tumor biopsy to predict response to neoadjuvant chemoradiotherapy in rectal cancer

Sutton, P. A., Jones, R., Hamid, B., Abbott, G., Goldring, C., Palmer, D. H., . . . Vimalachandran, D. (2014). Proteomic profiling of the diagnostic tumor biopsy to predict response to neoadjuvant chemoradiotherapy in rectal cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.e14579

DOI
10.1200/jco.2014.32.15_suppl.e14579
Conference Paper

Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-kappa B activation via a negative feedback loop

Elmetwali, T., Young, L. S., & Palmer, D. H. (2014). Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-kappa B activation via a negative feedback loop. CELL DEATH & DISEASE, 5. doi:10.1038/cddis.2014.172

DOI
10.1038/cddis.2014.172
Journal article

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.

Valle, J., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., . . . Büchler, M. W. (2014). Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.. Journal of Clinical Oncology, 32(6), 504-512. doi:10.1200/JCO.2013.50.7657

DOI
10.1200/JCO.2013.50.7657
Journal article

Cardiopulmonary exercise testing before liver surgery

Dunne, D. F. J., Jones, R. P., Lythgoe, D. T., Pilkington, F. J., Palmer, D. H., Malik, H. Z., . . . Fenwick, S. W. (2014). Cardiopulmonary exercise testing before liver surgery. JOURNAL OF SURGICAL ONCOLOGY, 110(4), 439-444. doi:10.1002/jso.23670

DOI
10.1002/jso.23670
Journal article

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., . . . Büchler, M. W. (2014). Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.. Journal of the National Cancer Institute, 106(1). doi:10.1093/jnci/djt347

DOI
10.1093/jnci/djt347
Journal article

The ART strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE

Yousuf, F., Cross, T. J. S., & Palmer, D. (2014). The ART strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. JOURNAL OF HEPATOLOGY, 61(1), 175. doi:10.1016/j.jhep.2014.02.032

DOI
10.1016/j.jhep.2014.02.032
Journal article

The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers

Johnson, P. J., Pirrie, S. J., Cox, T. F., Berhane, S., Teng, M. J., Palmer, D. H., . . . Satomura, S. (2014). The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiology, Biomarkers and Prevention, 23(1), 144-153. doi:10.1158/1055-9965.EPI-13-0870

DOI
10.1158/1055-9965.EPI-13-0870
Journal article

2013

Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: A review of mechanisms and outcomes

McWhirter, D., Kitteringham, N., Jones, R. P., Malik, H., Park, K., & Palmer, D. (2013). Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: A review of mechanisms and outcomes. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 88(2), 404-415. doi:10.1016/j.critrevonc.2013.05.011

DOI
10.1016/j.critrevonc.2013.05.011
Journal article

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom

Palmer, D. H., Hussain, S. A., Smith, A. J., Hargreaves, S., Ma, Y. T., Hull, D., . . . Ross, P. J. (2013). Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. BRITISH JOURNAL OF CANCER, 109(4), 888-890. doi:10.1038/bjc.2013.410

DOI
10.1038/bjc.2013.410
Journal article

Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization

Palmer, D. H. (2013). Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization. JOURNAL OF CLINICAL ONCOLOGY, 31(21), 2756. doi:10.1200/JCO.2013.49.8352

DOI
10.1200/JCO.2013.49.8352
Journal article

Peptide receptor radionuclide therapy with <SUP>90</SUP>Y-DOTATATE/<SUP>90</SUP>Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity

Vinjamuri, S., Gilbert, T. M., Banks, M., McKane, G., Maltby, P., Poston, G., . . . Cuthbertson, D. J. (2013). Peptide receptor radionuclide therapy with <SUP>90</SUP>Y-DOTATATE/<SUP>90</SUP>Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. BRITISH JOURNAL OF CANCER, 108(7), 1440-1448. doi:10.1038/bjc.2013.103

DOI
10.1038/bjc.2013.103
Journal article

2012

Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial

Neoptolemos, J. P., Moore, M. J., Cox, T. F., Valle, J. W., Palmer, D. H., McDonald, A. C., . . . Buechler, M. W. (2012). Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 308(2), 147-156. doi:10.1001/jama.2012.7352

DOI
10.1001/jama.2012.7352
Journal article

A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer

Hussain, S. A., Palmer, D. H., Lloyd, B., Collins, S. I., Barton, D., Ansari, J., & James, N. D. (2012). A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. ONCOLOGY LETTERS, 3(4), 855-859. doi:10.3892/ol.2012.563

DOI
10.3892/ol.2012.563
Journal article

A multicentre, open label, phase I study to evaluate safety and pharmacokinetics of BIBF 1120 for patients with advanced hepatocellular carcinoma

Palmer, D. H., Loembe, A. B., Studeny, M., & Meyer, T. (2012). A multicentre, open label, phase I study to evaluate safety and pharmacokinetics of BIBF 1120 for patients with advanced hepatocellular carcinoma.

Journal article

Fas-associated Factor 1 (FAF1) is a novel CD40 interactor that contributes to NFkappaB regulation via a negative feedback loop

Elmetwali, T., Young, L. S., & Palmer, D. H. (2012). Fas-associated Factor 1 (FAF1) is a novel CD40 interactor that contributes to NFkappaB regulation via a negative feedback loop.

Journal article

2011

Cytotoxic Chemotherapy and Endocrine Therapy for Hepatocellular Carcinoma

Palmer, D., & Johnson, P. J. (2011). Cytotoxic Chemotherapy and Endocrine Therapy for Hepatocellular Carcinoma. In Hepatocellular Carcinoma: (pp. 337-353). Springer New York. doi:10.1007/978-1-60327-522-4_21

DOI
10.1007/978-1-60327-522-4_21
Chapter

2010

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial

Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., . . . Buechler, M. W. (2010). Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 304(10), 1073-1081. doi:10.1001/jama.2010.1275

DOI
10.1001/jama.2010.1275
Journal article

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., . . . ABC-02 Trial Investigators. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.. The New England journal of medicine, 362(14), 1273-1281. doi:10.1056/nejmoa0908721

DOI
10.1056/nejmoa0908721
Journal article

CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus.

Elmetwali, T., Searle, P. F., McNeish, I., Young, L. S., & Palmer, D. H. (2010). CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus.. Molecular cancer, 9, 52. doi:10.1186/1476-4598-9-52

DOI
10.1186/1476-4598-9-52
Journal article

A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.

Meyer, T., Caplin, M. E., Palmer, D. H., Valle, J. W., Larvin, M., Waters, J. S., . . . Kato, H. (2010). A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.. European journal of cancer (Oxford, England : 1990), 46(3), 526-533. doi:10.1016/j.ejca.2009.11.004

DOI
10.1016/j.ejca.2009.11.004
Journal article

CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals.

Elmetwali, T., Young, L. S., & Palmer, D. H. (2010). CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals.. Journal of immunology (Baltimore, Md. : 1950), 184(2), 1111-1120. doi:10.4049/jimmunol.0900528

DOI
10.4049/jimmunol.0900528
Journal article

2009

Role of Tyrosine Kinase Inhibitors in Lung Cancer

Ansari, J., Palmer, D. H., Rea, D. W., & Hussain, S. A. (2009). Role of Tyrosine Kinase Inhibitors in Lung Cancer. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 9(5), 569-575. doi:10.2174/187152009788451879

DOI
10.2174/187152009788451879
Journal article

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

Palmer, D. H., Midgley, R. S., Mirza, N., Torr, E. E., Ahmed, F., Steele, J. C., . . . Adams, D. H. (2009). A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.. Hepatology (Baltimore, Md.), 49(1), 124-132. doi:10.1002/hep.22626

DOI
10.1002/hep.22626
Journal article

2008

The clinical management of hepatic neoplasms

Palmer, D., & Johnson, P. (2008). The clinical management of hepatic neoplasms. In Interventional Radiological Treatment of Liver Tumors (pp. 1-24). Cambridge University Press. doi:10.1017/cbo9780511575433.003

DOI
10.1017/cbo9780511575433.003
Chapter

Biology of testicular germ cell tumors

Hussain, S. A., Ma, Y. T., Palmer, D. H., Hutton, P., & Cullen, M. H. (2008). Biology of testicular germ cell tumors. EXPERT REVIEW OF ANTICANCER THERAPY, 8(10), 1659-1673. doi:10.1586/14737140.8.10.1659

DOI
10.1586/14737140.8.10.1659
Journal article

Hepatocellular Carcinoma: Medical Management

Johnson, P., & Palmer, D. (2008). Hepatocellular Carcinoma: Medical Management. In Interventional Oncology (pp. 115-120). Cambridge University Press. doi:10.1017/cbo9780511722226.012

DOI
10.1017/cbo9780511722226.012
Chapter

Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer

Palmer, D. H., Stocken, D. D., Hewitt, H., Markham, C. E., Hassan, A. B., Johnson, P. J., . . . Bramhall, S. R. (2008). Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer. Annals of Surgical Oncology, 15(7), 2061. doi:10.1245/s10434-008-9921-2

DOI
10.1245/s10434-008-9921-2
Journal article

Liver

Liver (2008). In Treatment of Cancer (pp. 583-596). CRC Press. doi:10.1201/b13550-29

DOI
10.1201/b13550-29
Chapter

Genomics and Pharmacogenomics in the Management of Breast Cancer

Hussain, S., Pascoe, J., Palmer, D., Spooner, D., & Rea, D. (2008). Genomics and Pharmacogenomics in the Management of Breast Cancer. Current Pharmacogenomics and Personalized Medicine, 6(1), 45-55. doi:10.2174/187569208784017485

DOI
10.2174/187569208784017485
Journal article

A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting

Hussain, S. A., Palmer, D. H., Swinson, D. E., Riley, P., Wills, A., Brown, C., . . . Cullen, M. H. (2008). A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting. ONCOLOGY REPORTS, 20(1), 233-237. Retrieved from https://www.webofscience.com/

Journal article

2007

Molecularly targeted therapeutics for breast cancer

Hussain, S. A., Palmer, D. H., Spooner, D., & Rea, D. W. (2007). Molecularly targeted therapeutics for breast cancer. BIODRUGS, 21(4), 215-224. doi:10.2165/00063030-200721040-00002

DOI
10.2165/00063030-200721040-00002
Journal article

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

Palmer, D. H., Stocken, D. D., Hewitt, H., Markham, C. E., Hassan, A. B., Johnson, P. J., . . . Bramhall, S. R. (2007). A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.. Annals of surgical oncology, 14(7), 2088-2096. doi:10.1245/s10434-007-9384-x

DOI
10.1245/s10434-007-9384-x
Journal article

Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX

Hussain, S. A., Rea, D. W., & Palmer, D. H. (2007). Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX. BRITISH JOURNAL OF CANCER, 96(8), 1310. doi:10.1038/sj.bjc.6603716

DOI
10.1038/sj.bjc.6603716
Journal article

Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer

Hussain, S. A., Ganesan, R., Reynolds, G., Gross, L., Stevens, A., Pastorek, J., . . . Palmer, D. H. (2007). Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. BRITISH JOURNAL OF CANCER, 96(1), 104-109. doi:10.1038/sj.bjc.6603530

DOI
10.1038/sj.bjc.6603530
Journal article

Signal transduction therapy: Challenges to clinical trial design

Hussain, S. A., Rea, D. W., James, N. D., & Palmer, D. H. (2007). Signal transduction therapy: Challenges to clinical trial design. CURRENT SIGNAL TRANSDUCTION THERAPY, 2(1), 21-30. doi:10.2174/157436207779317137

DOI
10.2174/157436207779317137
Journal article

2005

Role of chemotherapy in breast cancer

Hussain, S. A., Palmer, D. H., Stevens, A., Spooner, D., Poole, C. J., & Rea, D. W. (2005). Role of chemotherapy in breast cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 5(6), 1095-1110. doi:10.1586/14737140.5.6.1095

DOI
10.1586/14737140.5.6.1095
Journal article

Gene- and immunotherapy for hepatocellular carcinoma

Palmer, D. H., Hussain, S. A., & Johnson, P. J. (2005). Gene- and immunotherapy for hepatocellular carcinoma. EXPERT OPINION ON BIOLOGICAL THERAPY, 5(4), 507-523. doi:10.1517/14712598.5.4.507

DOI
10.1517/14712598.5.4.507
Journal article

Pre-operative locoregional therapy and liver transplantation for hepatocellular carcinoma: time for a randomized controlled trial.

Palmer, D. H., & Johnson, P. J. (2005). Pre-operative locoregional therapy and liver transplantation for hepatocellular carcinoma: time for a randomized controlled trial.. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 5(4 Pt 1), 641-642. doi:10.1111/j.1600-6143.2005.00856.x

DOI
10.1111/j.1600-6143.2005.00856.x
Journal article

2004

Systemic therapies for hepatocellular carcinoma

Palmer, D. H., Hussain, S. A., & Johnson, P. J. (2004). Systemic therapies for hepatocellular carcinoma. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 13(12), 1555-1568. doi:10.1517/13543784.13.12.1555

DOI
10.1517/13543784.13.12.1555
Journal article

A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer

Hussain, S. A., Stocken, D. D., Riley, P., Palmer, D. H., Peake, D. R., Geh, J. I., . . . James, N. D. (2004). A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. BRITISH JOURNAL OF CANCER, 91(5), 844-849. doi:10.1038/sj.bjc.6602112

DOI
10.1038/sj.bjc.6602112
Journal article

CD40 expression in prostate cancer: A potential diagnostic and therapeutic molecule

Palmer, D. H., Hussain, S. A., Ganesan, R., Cooke, P. W., Wallace, D. M. A., Young, L. S., & James, N. D. (2004). CD40 expression in prostate cancer: A potential diagnostic and therapeutic molecule. ONCOLOGY REPORTS, 12(4), 679-682. Retrieved from https://www.webofscience.com/

Journal article

Carbonic anhydrase IX, a marker of hypoxia: Correlation with clinical outcome in transitional cell carcinoma of the bladder

Hussain, S. A., Palmer, D. H., Ganesan, R., Hiller, L., Gregory, J., Murray, P. G., . . . James, N. D. (2004). Carbonic anhydrase IX, a marker of hypoxia: Correlation with clinical outcome in transitional cell carcinoma of the bladder. ONCOLOGY REPORTS, 11(5), 1005-1010. Retrieved from https://www.webofscience.com/

Journal article

Endocrine therapy and other targeted therapies for metastatic breast cancer.

Hussain, S. A., Palmer, D. H., Moon, S., & Rea, D. W. (2004). Endocrine therapy and other targeted therapies for metastatic breast cancer.. Expert review of anticancer therapy, 4(6), 1179-1195. doi:10.1586/14737140.4.6.1179

DOI
10.1586/14737140.4.6.1179
Journal article

2001

Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954

Chung-Faye, G., Palmer, D., Anderson, D., Clark, J., Downes, M., Baddeley, J., . . . Kerr, D. J. (2001). Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. CLINICAL CANCER RESEARCH, 7(9), 2662-2668. Retrieved from https://www.webofscience.com/

Journal article